एथेरोस्क्लेरोसिस: ओपन एक्सेस

खुला एक्सेस

हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।

ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं

में अनुक्रमित
  • गूगल ज्ञानी
  • RefSeek
  • हमदर्द विश्वविद्यालय
  • ईबीएससीओ एज़
  • पबलोन्स
  • आईसीएमजेई
इस पृष्ठ को साझा करें

अमूर्त

Atrial Fibrillation in Intermediate CHA2DS2-Vasc Risk Group as a Cause of Thromboembolic Complications: Case Report

Grzegorz Sobieszek, Agnieszka Wójtowicz-Scislak, Bartolomeo Zerillo

Atrial Fibrillation (AF) is a common arrhythmia, especially for elderly people and it can lead to thromboembolic complications. A 42-year-old man was presented with the strong abdominal pain, radiating to the back and a fever. He had elevated troponin, NT-pro-BNP, D-dimer. Electrocardiography (ECG) showed Atrial Fibrillation (AF), and an echocardiography revealed a slight enlargement of both atria. A coronary angiography did not show significant lesions, requiring an invasive intervention. Trans-Esophageal Echocardiography (TEE) confirmed thrombus in the left auricle. An embolic material in the superior mesenteric artery and infarction of right kidney were found in Computed Tomography Angiography (CTA). Beside standard treatment of ischemic heart disease, the patient received a therapeutic dose of Low Molecular Weight Heparin (LMWH) in the acute period of disease and then the heparin was changed to Novel Oral AntiCoagulants (NOAC). Despite of a therapy two weeks later he developed the embolism of the lower limb and the infarction of the left kidney. Then the TEE did not confirm the thrombus, so electric cardioversion was performed.

According to CHA2DS2-VASc scale, the patient received 1 point, so the anticoagulation should be considered (but it was not obligatory), weighing the individual bleeding risk against the risk of stroke. It is valid to treat each patient individually and take into account thromboembolic diseases, not only in high-risk group.